Yes, that’s right. This is no longer sci-fi Twilight Zone talk. The capabilities of 3D Bioprinting are endless. Picture a world where we are able to grow liver in a lab from tissues and cells to be used for a transplant patient. The ability to engineer cells to grow into a heart valve to replace one that is damaged from heart disease is now becoming reality.
It may sound like science fiction, but already scientists at Cyfuse have bioprinted blood vessels able to withstand 10 times the pressure of those already in the human body, according to Koji Kuchiishi, co-founder and former CEO.
Bioprinting works like this: Scientists harvest human cells from biopsies or stem cells, then allow them to multiply in a petri dish. The resulting mixture, a sort of biological ink, is fed into a 3-D printer that is programmed to arrange different cell types and materials into a three-dimensional shape. Doctors hope that when placed into the body, these 3-D printed cells will integrate with existing tissue.
All over the globe, many research institution are hustling every day to make this happen. In Tokyo, Japan, the start Cyfuse Biomedial is currently emerging to develop these specific breakthroughs within the world of regenerative medicine. This market is projected to reach $101.3 billion by 2022.
Imagine what an outstanding scientific breakthrough this would be. In the US alone there are 118,950 people are registered in the Organ Procurement Transplantation Network. Sadly, 22 die each day while waiting to have an organ transplant. 3D Bioprinting may be the solution to this difficult supply and demand issue.